CO6781543A2 - Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie - Google Patents

Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie

Info

Publication number
CO6781543A2
CO6781543A2 CO13111806A CO13111806A CO6781543A2 CO 6781543 A2 CO6781543 A2 CO 6781543A2 CO 13111806 A CO13111806 A CO 13111806A CO 13111806 A CO13111806 A CO 13111806A CO 6781543 A2 CO6781543 A2 CO 6781543A2
Authority
CO
Colombia
Prior art keywords
methods
virus particles
surface proteins
glycosylation
simplified
Prior art date
Application number
CO13111806A
Other languages
English (en)
Inventor
Chi Huey Wong
Che Ma
Yung-Chieh Tseng
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6781543(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of CO6781543A2 publication Critical patent/CO6781543A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Abstract

Se proporcionan métodos para producción de partículas de virus con glucosilación simplificada en proteínas estructurales o de superficie. Cuando se utilizan como objetivos para producción de vacunas, la naturaleza conservada de dichos sitios genera vacunas que son más sensibles a mutaciones víricas. Se describe el uso de inhibidores de glucosilación para producción de virus con perfiles de glucosilación simplificados. Se proporciona una descripción de ejemplo de los virus de la influenza y métodos para producción de partículas de virus de influenza monoglucosilada. Se proporcionan métodos para producción de formas monoglucosiladas de virus de influenza A, NIBRG-14 (H5N1).
CO13111806A 2010-11-04 2013-05-03 Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie CO6781543A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41025710P 2010-11-04 2010-11-04

Publications (1)

Publication Number Publication Date
CO6781543A2 true CO6781543A2 (es) 2013-10-31

Family

ID=46024856

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13111806A CO6781543A2 (es) 2010-11-04 2013-05-03 Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie

Country Status (17)

Country Link
US (2) US9403878B2 (es)
EP (1) EP2635693B1 (es)
JP (2) JP6166178B2 (es)
KR (2) KR102156209B1 (es)
CN (2) CN108165534A (es)
AU (2) AU2011323141B2 (es)
BR (1) BR112013011198B1 (es)
CA (2) CA2854619C (es)
CL (1) CL2013001219A1 (es)
CO (1) CO6781543A2 (es)
DK (1) DK2635693T3 (es)
ES (1) ES2831256T3 (es)
IL (1) IL226143B (es)
MX (1) MX349530B (es)
RU (1) RU2607452C2 (es)
TW (1) TWI537385B (es)
WO (1) WO2012061776A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756206A1 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
WO2023238756A1 (ja) * 2022-06-07 2023-12-14 国立大学法人 東京大学 ウイルス粒子検出方法、情報処理装置及びウイルス粒子検出プログラム

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953592A (en) * 1973-09-27 1976-04-27 Recherche Et Industrie Therapeutiques (R.I.T.) Live influenza virus vaccines and preparation thereof
US4318903A (en) * 1978-07-12 1982-03-09 Smithkline-Rit Live influenza virus vaccine and the preparation thereof
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
EP0272253A4 (en) * 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US6103238A (en) 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
ATE290592T1 (de) 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
US20020045594A1 (en) 1997-02-14 2002-04-18 Merck & Co., Inc. Polynucleotide vaccine formulations
US6908617B1 (en) 1997-11-10 2005-06-21 Dana-Farber Cancer Institute, Inc. Glycosylated modified primate lentivirus envelope polypeptides
DK1183044T3 (da) 1999-05-12 2007-12-27 Statens Seruminstitut Adjuvanskombinationer til immunisering og vacciner
FR2799974B1 (fr) 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
EP1267920B1 (en) 2000-04-03 2007-01-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions comprising cold-adapted equine influenza viruses for the treatment of existing viral infections of the respiratory system.
DK1294910T3 (da) 2000-06-30 2009-03-02 Vib Vzw Protein glykosyleringsmodifikation i Pichia Pastoris
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
EP1461445B1 (en) * 2001-11-28 2008-08-20 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US7442375B2 (en) 2002-12-13 2008-10-28 Case Western Reserve University Compositions of beta-defensin inducing agents
ATE547511T1 (de) * 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
EP2058004A1 (en) * 2005-03-16 2009-05-13 University of Oxford Mannose immunogens for HIV-1
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
US20080118529A1 (en) 2005-07-13 2008-05-22 Gebbink Martijn Frans Ben Gera Adjuvation Through Cross -Beta Structure
AU2006316838B2 (en) 2005-11-15 2012-04-12 Glycofi, Inc Production of glycoproteins with reduced O-glycosylation
ES2310072B1 (es) 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007133855A2 (en) * 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
WO2007150054A2 (en) 2006-06-24 2007-12-27 Mrugesh Shah Immunogenic compositions having altered glycosylations
CA2660038A1 (en) 2006-08-14 2008-06-19 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2008112017A2 (en) 2006-10-10 2008-09-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healtand Human Services Avian influenza vaccine
US20090017052A1 (en) 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US7928068B2 (en) 2007-01-31 2011-04-19 New York University Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders
CA2756206A1 (en) * 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
RU2011142230A (ru) * 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
US20120219584A1 (en) * 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法

Also Published As

Publication number Publication date
CN103476942A (zh) 2013-12-25
AU2016204276A1 (en) 2016-07-14
BR112013011198B1 (pt) 2022-03-15
TW201307560A (zh) 2013-02-16
JP6166178B2 (ja) 2017-07-19
IL226143A0 (en) 2013-06-27
TWI537385B (zh) 2016-06-11
AU2011323141A1 (en) 2013-06-27
KR102156209B1 (ko) 2020-09-17
MX2013004996A (es) 2014-02-27
RU2607452C2 (ru) 2017-01-10
WO2012061776A1 (en) 2012-05-10
BR112013011198A2 (pt) 2016-07-05
US20160348144A1 (en) 2016-12-01
AU2011323141B2 (en) 2016-04-07
CA2854619A1 (en) 2012-05-10
CL2013001219A1 (es) 2014-04-04
KR20130115292A (ko) 2013-10-21
EP2635693A4 (en) 2014-05-07
EP2635693B1 (en) 2020-10-07
MX349530B (es) 2017-08-02
US20140011188A1 (en) 2014-01-09
CN108165534A (zh) 2018-06-15
DK2635693T3 (da) 2020-12-21
CA3147075A1 (en) 2012-05-10
US9403878B2 (en) 2016-08-02
RU2013125590A (ru) 2014-12-10
KR101927421B1 (ko) 2018-12-10
IL226143B (en) 2020-04-30
JP6773513B2 (ja) 2020-10-21
AU2016204276B2 (en) 2017-10-26
JP2017031204A (ja) 2017-02-09
JP2014500012A (ja) 2014-01-09
CA2854619C (en) 2022-02-01
EP2635693A1 (en) 2013-09-11
US9920347B2 (en) 2018-03-20
ES2831256T3 (es) 2021-06-08
KR20180132981A (ko) 2018-12-12

Similar Documents

Publication Publication Date Title
CL2016000381A1 (es) Compuestos antivirales
UY35266A (es) Compuestos antivirales
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2016002413A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
ZA201505608B (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
MX2014003308A (es) Vacunas para el virus de la influenza y usos de las mismas.
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
MX2015008861A (es) Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.
CL2016003181A1 (es) Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).
CO6781543A2 (es) Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie
CL2016000300A1 (es) Métodos terapéuticos
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
EA201400235A1 (ru) Вакцины против гриппа на основе н5
UY35390A (es) Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
CL2022001176A1 (es) Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
MX2020004305A (es) Linea celular eucariota.